Iterum Therapeutics to Present Data at IDWeek 2023
October 12 2023 - 9:15AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that three posters will be presented at
the Infectious Disease Society of America’s IDWeek 2023 conference
taking place in Boston, MA from October 11-15, 2023.
Data to be presented at IDWeek 2023 include:
Presentation Title: Desirability
of Outcome Ranking (DOOR): Application to a Phase 3 Registrational
Trial Evaluating Sulopenem for Patients with Complicated
Intra-abdominal Infection (cIAI)Poster
#: 2016Presenter: Steven
I. Aronin, MDTime/Location: Saturday,
October 14, 12:15 p.m. - 1:30 p.m.
Presentation
Title: Characterization of Sulopenem
Pharmacokinetics-Pharmacodynamics Using a One-Compartment
In Vitro Infection
ModelPoster #:
2568Presenter: Brian
D. VanScoy, BSTime/Location: Saturday,
October 14, 12:15 p.m. - 1:30 p.m.
Presentation
Title: Pharmacokinetic-Pharmacodynamic
Evaluation of Sulopenem Using a Five-Day Hollow-Fiber
In Vitro Infection
ModelPoster #:
2569Presenter: Brian D.
VanScoy, BSTime/Location: Saturday, October
14, 12:15 p.m. - 1:30 p.m.
These Posters will be made available on the
Company’s website on the “Publications: Posters &
Presentations” page under the “Our Science” tab once the conference
ends.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024